Cardiff Oncology
San Diego
About Cardiff Oncology
Cardiff Oncology is a clinical-stage oncology therapeutics company developing drugs that target cell division for the treatment of leukemias, lymphomas, and solid tumor cancers. It has a broad intellectual property and proprietary technology to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies. The company offers its PCM technology at its CLIA/CAP-accredited laboratory and plans to continue to vertically integrate its PCM technology with precision cancer therapeutics. Cardiff Oncology (formerly known as Trovagene) was founded in 1999 and is headquartered in San Diego, California.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $120.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2024)
- Ticker: nasdaq:CRDF
- Website: cardiffoncology.com
- Phone: +1 858-952-7570
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Medical, Oncology
Social Profiles
Canonical: https://fsome.com/organization/cardiff-oncology-121854 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.